Pfizer, CDC create initiative to combat drug-resistant infections
NEWS IN BRIEF — Posted Nov. 14, 2005
In order to address the increasing problem of methicillin-resistant Staphylococcus aureus, that has emerged in the community over the past few years, Pfizer Inc., with the support of the Centers for Disease Control and Prevention, has launched the MRSA Leadership Initiative.
The initiative is an interdisciplinary group of epidemiology, infectious disease and health policy experts.
The hope is to create programs that increase awareness of MRSA, determine directions for research that could lead to better tools to manage this bug and establish projects that will work to prevent these kind of infections.
"This multiyear commitment will help get proven, life-saving improvement techniques put into action," said Denise Cardo, MD, director of the CDC's division of health care quality promotion. "MRSA is a priority for the public health community."
Note: This item originally appeared at http://www.ama-assn.org/amednews/2005/11/14/hlbf1114.htm.